The global antibody therapeutics market is rapidly evolving.

Do date, Y-Biologics has secured leading technologies in the field of antibody discovery and achieved numerous technological milestones based on this foundation.

Currently, there are two major global trends in the biopharmaceutical industry concerning antibody drugs.

The first is the development of next-generation antibody therapies that overcome the limited efficacy shown by existing immune checkpoint inhibitors such as anti-PD-1 antibodies.

The second is the improvement of safety in ADCs (Antibody-Drug Conjugates) which, despite their high potential, face challenges with respect to toxicity and off-target effects.

In response to these market trends, Y-Biologics is actively developing multi-specific antibodies that overcome the limitations of conventional immuno-oncology therapies, based on the latest research findings.

We are also focusing on the development of next-generation antibodies for ADCs that maximize both safety and therapeutic efficacy.

Through our proprietary antibody technology and differentiated research strategies, Y-Biologics aims to lead the global antibody drug development sector and contribute to realizing healthier lives for everyone.